Salus Therapeutics focuses on the development of new anti-infective and oncology new drugs through the 505(b)(2) regulatory pathway. By leveraging existing clinical safety and pharmacological data of approved drugs, and combining them with new formulations or new indications, the company significantly shortens R&D timelines and reduces the resources required for clinical trials. Its focus is on diseases with insufficient efficacy, high risk of side effects, or limited treatment options, aiming to develop clinically valuable new therapies by repositioning and optimizing existing drugs.